OAM
CYCN icon

Oxford Asset Management’s Cyclerion Therapeutics CYCN Stock Holding History

Oxford Asset Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-589
Closed -$32K – 488
2019
Q4 		$32K Buy
+589
New +$55K ﹤0.01% 1683

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Oxford Asset Management's CYCN Position: Q1 2020 in Review

Oxford Asset Management sold out of Cyclerion Therapeutics (CYCN) in Q1 2020, closing a stake of 589 shares — an estimated $32K sold.

Oxford Asset Management first reported a position in CYCN in Q4 2019 and held it in 1 quarter. The position peaked at $32K in Q4 2019. 80 funds tracked by Wall St. Rank hold CYCN as of Q1 2020.

  • Oxford Asset Management reported no remaining Cyclerion Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 589 Cyclerion Therapeutics shares in Q1 2020, an estimated $32K.
  • Oxford Asset Management first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 1 quarter.
  • Oxford Asset Management's Cyclerion Therapeutics position peaked at $32K in Q4 2019.
  • 80 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.